horse anti-human T lymphocyte immunoglobulin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
horse anti-human T lymphocyte immunoglobulin: clinical details
Prescribing considerations
- Restrict use to clinicians experienced in immunosuppressive treatment of aplastic anaemia and facilities with inpatient laboratory and emergency support.
- Assess infection status and the cumulative effect of accompanying immunosuppression.
- Skin testing before treatment is strongly recommended to identify increased anaphylaxis risk, although a negative test does not exclude a reaction.
- Record the product name and batch number for biological traceability.
- Consider sodium contributed by the infusion diluent when clinically relevant.
Contraindications and cautions
- Hypersensitivity to horse anti-human T lymphocyte immunoglobulin or any excipient.
- Hypersensitivity to another horse gamma-globulin preparation.
- A systemic reaction such as generalised rash, tachycardia, dyspnoea, hypotension or anaphylaxis precludes further administration.
Monitoring
- Observe continuously during and after infusion for allergic reactions and cytokine-release syndrome.
- Check full blood count before, during and after treatment, with particular attention to neutrophils and platelets.
- Monitor for bacterial, fungal and viral infection or reactivation.
- Monitor renal and liver function.
- Ensure immediate access to treatment for anaphylaxis and other severe infusion reactions.
Clinical pharmacology
A horse-derived polyclonal immunoglobulin preparation that binds multiple lymphocyte-surface proteins. Its principal immunosuppressive effect is depletion and functional suppression of circulating lymphocytes, especially T lymphocytes, through mechanisms including complement-dependent lysis and apoptosis.
Formulation and product differences
- The selected product is a sterile concentrate that requires dilution before intravenous infusion.
- It contains horse-derived immunoglobulin with glycine and water for injections; sodium hydroxide and hydrochloric acid are used for pH adjustment.
- It is essentially sodium-free before dilution, but preparation fluids may contain sodium.
- Because protein particles may develop during storage, every infusion requires an in-line filter and the product must not be shaken.
horse anti-human T lymphocyte immunoglobulin preparations and strengths
Solution for infusion
Route: Intravenous
Strengths: 50 mg/mL
horse anti-human T lymphocyte immunoglobulin interactions
Formal interaction studies have not been performed. The specialist team should review all medicines and planned vaccinations.
Vaccines
Vaccination during treatment is not recommended because immune suppression may reduce vaccine effectiveness; timing should be agreed with the specialist team.
Other immunosuppressants, including ciclosporin
Combined immune suppression can increase infection risk and requires close specialist monitoring.
Corticosteroids and other immunosuppressants being reduced
Previously masked reactions may become apparent during dose reduction, so continued observation is required.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.